ClinicalTrials.gg
RecruitingNCT07604571Updated Nov 3, 2026

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

A Phase 1 interventional study of IEV407 and Fulvestrant in Advanced HR+/HER2- Breast Cancer, sponsored by Novartis Pharmaceuticals. Recruiting at 12 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Nov 3, 2026First sites in 4 new countries6 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
194
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 199 studies in Breast Neoplasms by Novartis — 16 open to participants now, 30 under way, 4 of them phase 3. Breast Neoplasms · Novartis.

Planned enrollment
60th of 155
194 · median 104
Started
2026
with 9 others
Phase 1
40 of 199
6 open now
Primary completion
2032-06
later than 28 of 29 live
Registered
193rd of 199
by date

Among the 199 studies in Breast Neoplasms by Novartis, this one is the 60th largest by planned enrollment of the 155 interventional ones that give a count, is one of 10 that started in 2026, is one of 40 in phase 1, reaches primary completion later than 28 of the 29 other live ones, and was the 193rd registered.

Breast Neoplasms

14,832 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

16 of the 199 studies in Breast Neoplasms by Novartis are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 199 studies in Breast Neoplasms by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability and preliminary activity of IEV407 as a single agent and in combination with endocrine therapy (fulvestrant or letrozole) in patients with advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-negative) breast cancer.

Read the detailed description

This is a first-in-human, open-label, phase I/Ib, multi-center study consisting of a dose escalation part of IEV407 as a single agent (SA) and in combination with endocrine therapy (fulvestrant or letrozole) followed by a dose expansion part in patients with advanced breast cancer (aBC). The study will start with the evaluation of IEV407 as a SA.

Following evaluation of IEV407 in combination with fulvestrant through dose escalation and establishment of a recommended dose and/or dose ranges for optimization (RD/DRO), the study may proceed to the Phase Ib expansion part to evaluate the combination treatment of IEV407 with fulvestrant. If more than one treatment arm is open concurrently in the dose expansion part, a randomization schedule will be employed for patient allocation.

03

Conditions studied

  • Advanced HR+/HER2- Breast Cancer

Browse trials for

Keywords

  • IEV407
  • HR+/HER2- advanced breast cancer
  • letrozole
  • fulvestrant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old
  • Patients with one of the following indications:

    • Dose escalation (IEV407 single agent and in combination with fulvestrant or letrozole):

HR+/- aBC with disease progression on or following, or have been intolerant to, at least one line of endocrine-based therapy in combination with a CDK4/6 inhibitor and at least one additional in the unresectable/ setting and not be a candidate for any available standard therapy, in the investigator's judgement.

- Dose expansion of IEV407 in combination with fulvestrant: HR+/HER2- aBC with disease progression on or following, or have been intolerant to, endocrine-based therapy in combination with a CDK4/6 inhibitor. They must not have received more than two prior lines of endocrine-based therapy in the unresectable/metastatic setting. Prior cytotoxic chemotherapy and/or antibody-drug conjugate therapies in the unresectable/metastatic setting are not allowed.

Exclusion criteria

Exclusion Criteria:

  • Patients with inadequate bone marrow and/or organ functions with out-of-range laboratory values.
  • Impaired cardiac function or cardiac disease.
  • Concurrent use of hormone replacement therapy.
  • Women of who are unwilling to use highly effective methods, pregnant or nursing women.
  • For the combination treatment of IEV407 with fulvestrant or letrozole: Patients with symptomatic visceral disease or any disease burden that makes the patient ineligible for endocrine-based therapy.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
194 participants (estimated)

Study arms

  • Experimental
    Dose escalation: IEV407 single agent

    IEV407 single agent

    Drug: IEV407

  • Experimental
    Dose escalation: IEV407 + fulvestrant

    IEV407 in combination with fulvestrant

    Drug: IEV407 · Drug: Fulvestrant

  • Experimental
    Dose escalation: IEV407 + letrozole

    IEV407 in combination with letrozole

    Drug: IEV407 · Drug: Letrozole

  • Experimental
    Dose expansion, recommended dose (RD)-1: IEV407 + fulvestrant

    IEV407 in combination with fulvestrant

    Drug: IEV407 · Drug: Fulvestrant

  • Experimental
    Dose expansion, RD-2 (optional dose optimization): IEV407 + fulvestrant

    IEV407 in combination with fulvestrant

    Drug: IEV407 · Drug: Fulvestrant

Interventions

  • DrugIEV407

    Oral administration

  • Intramuscular injection. Approved medication.

    Also known as: Faslodex

  • Oral administration. Approved medication.

    Also known as: Femara

06

What researchers measure

Primary outcomes

  1. Incidence and severity of dose-limiting toxicities (DLTs)

    Number of participants with DLTs. A DLT is defined as an adverse event or abnormal laboratory value of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher, including death, unless clearly and incontrovertibly assessed as due to disease, disease progression, inter-current illness/injury, concomitant medications, or extraneous causes, that occurs within the first 28 days of treatment with IEV407 in the dose escalation parts or in the expansion part of IEV407 in combination with fulvestrant with the exceptions described in the study protocol.

    Time frame: 28 days

  2. Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Number of participants with AEs and SAEs, including changes in laboratory values, vital signs and echocardiograms (ECGs) qualifying and reported as AEs.

    Time frame: Up to approximately 2 years

  3. Frequency of dose interruptions, reductions and discontinuations

    Number of participants with dose adjustments (interruptions, reductions, or permanent discontinuation) as a measure of tolerability.

    Time frame: Up to approximately 2 years

  4. Dose intensity

    Dose intensity defined as the ratio of actual cumulative dose received and actual duration of exposure.

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Best Overall Response (BOR)

    BOR per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) is defined as the best overall confirmed response recorded from the start of the treatment until progressive disease (PD), death, start of new therapy, withdrawal of consent or end of study, whatever comes first. Efficacy will be based on the investigator assessment.

    Time frame: Up to approximately 2 years

  2. Overall Response Rate (ORR)

    ORR per RECIST v1.1 is defined as the proportion of patients with a BOR of Complete response (CR) or Partial response (PR). Efficacy will be based on the investigator assessment.

    Time frame: Up to approximately 2 years

  3. Disease Control Rate (DCR)

    DCR per RECIST v1.1 is defined as the proportion of patients with a BOR of CR, PR, or Stable Disease (SD). Efficacy will be based on the investigator assessment.

    Time frame: Up to approximately 2 years

  4. Clinical Benefit Rate (CBR)

    CBR per RECIST v1.1 is defined as the proportion of patients with a BOR of CR, PR, or an overall lesion response of SD or Non-CR/Non-PD which lasts for at least 24 weeks. Efficacy will be based on the investigator assessment.

    Time frame: Up to approximately 2 years

  5. Duration of Response (DOR)

    DOR per RECIST v1.1 is the time between the first documented response (CR or PR) and the date of progression by local review as applicable or death due to any cause. Efficacy will be based on the investigator assessment.

    Time frame: Up to approximately 2 years

  6. Progression Free Survival (PFS)

    PFS per RECIST 1.1 is defined as the time from the date of start of study treatment (Phase I) or the date of randomization (Phase II) to the date of the first documented progression or death due to any cause. Efficacy will be based on the investigator assessment.

    Time frame: Up to approximately 2 years

  7. Maximum plasma concentration (Cmax) of IEV407

    Pharmacokinetic (PK) parameters based on plasma concentrations of IEV407.

    Time frame: From pre-dose up to 24 hours after dosing on Cycle 1 Day 1 and Day 15. 1 cycle = 28 days

  8. Area under the plasma concentration-time curve (AUC) of IEV407

    PK parameters based on plasma concentrations of IEV407.

    Time frame: From pre-dose up to 24 hours after dosing on Cycle 1 Day 1 and Day 15. 1 cycle = 28 days

07

Study locations

12 of 12 sites recruiting
  • Yale New Haven Hospital
    New Haven, Connecticut 06520, United States
    Recruiting
  • Univ of Kansas Hosp and Med Ctr
    Kansas City, Kansas 66160, United States
    Recruiting
    • LeAnn Nguyen · Contactlnguyen14@kumc.edu · +1 913 588 2566
    • Anne O Dea · Principal investigator
  • Mary Crowley Cancer Research
    Dallas, Texas 75251, United States
    Recruiting
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
  • Novartis Investigative Site
    Marseille, 13273, France
    Recruiting
  • Novartis Investigative Site
    Toulouse, 31059, France
    Recruiting
  • Novartis Investigative Site
    Ancona, AN 60020, Italy
    Recruiting
  • Novartis Investigative Site
    Hirakata, Osaka 5731191, Japan
    Recruiting
  • Novartis Investigative Site
    Leiden, South Holland 2333 ZA, Netherlands
    Recruiting
  • Novartis Investigative Site
    Singapore, 119074, Singapore
    Recruiting
  • Novartis Investigative Site
    Seoul, Seoul 06351, South Korea
    Recruiting
  • Novartis Investigative Site
    Madrid, 28034, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.

No publications or documents are linked to this record.

09

Timeline

6 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jun 2032, 72 months after the start.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 72 months is above that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2026
First posted
May 22, 2026
StartActual
May 28, 2026
Primary completionEst.
Jun 8, 2032
CompletionEst.
Jun 8, 2032
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added — first sites in France, Italy, Netherlands and Spain
Show 6 added (2 France, 1 United States, 1 Italy, 1 Netherlands, 1 Spain)
  • Novartis Investigative Site · Marseille, France
  • Univ of Kansas Hosp and Med Ctr · Kansas City, United States
  • Novartis Investigative Site · Toulouse, France
  • Novartis Investigative Site · Ancona, Italy
  • Novartis Investigative Site · Leiden, Netherlands
  • Novartis Investigative Site · Madrid, Spain
across 6 updates, Oct 5, 2026 – Nov 3, 2026
Show all 6 updates
  1. Nov 3, 2026
    1 site added — first site in Spain
    Show site
    • Novartis Investigative Site · Madrid, Spain
    + 1 other change: verification date
  2. Oct 29, 2026
    1 site added — first site in Netherlands
    Show site
    • Novartis Investigative Site · Leiden, Netherlands
  3. Oct 20, 2026
    1 site added — first site in Italy
    Show site
    • Novartis Investigative Site · Ancona, Italy
  4. Oct 19, 2026
    1 site added
    Show site
    • Novartis Investigative Site · Toulouse, France
  5. Oct 9, 2026
    1 site added
    Show site
    • Univ of Kansas Hosp and Med Ctr · Kansas City, United States
  6. Oct 5, 2026
    1 site added — first site in France
    Show site
    • Novartis Investigative Site · Marseille, France
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07604571
Responsible party
Sponsor
First posted
May 22, 2026
Start date
May 28, 2026
Primary completion
Jun 8, 2032 (estimated)
Completion
Jun 8, 2032 (estimated)
Last update
Nov 3, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
+41613241111

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion